Amgen IncAMGN
▼ NegativeRegulationCapitalrelevance
Voluntary nationwide recalls of Corlanor and Sensipar due to foreign substances and CGMP deviations raise drug quality and compliance risks.
Impact on stocks 1
Biotech & Genomic Medicine
Amgen IncAmgen has initiated voluntary nationwide recalls of certain Corlanor and Sensipar tablet lots due to foreign substances and CGMP deviations, prompting investors to reassess drug quality and compliance risks. The most popular Amgen narrative suggests the stock is about 4.5% overvalued versus a fair value of $352, while the Simply Wall St DCF model indicates the shares trade around 45.8% below an intrinsic value of $679.47. Amgen last closed at $368.10, with a 30-day share price return of 5.30% and a year-to-date return of 12.35%. The company's robust late-stage pipeline, including MariTide for obesity and type 2 diabetes, Repatha and olpasiran for cardiovascular conditions, and multiple bispecific T-cell engagers for oncology, positions it to launch high-margin, first-in-class products. However, drug pricing reforms and rising biosimilar competition could challenge revenue assumptions and the premium P/E multiple in the prevailing narrative.
Amgen IncVoluntary nationwide recalls of Corlanor and Sensipar due to foreign substances and CGMP deviations raise drug quality and compliance risks.